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Abstract 
 
Accessory parotid gland (APG) is salivary tissue that is anterior and anatomically separate 
from the parotid gland. Although the APG is a common anatomical variation, APG tumours 
are extremely rare. We report on 6 patients having APG tumours with emphasis on 
diagnosis, clinical features, indications and rationales for different treatment approaches. 
Patients with primary tumours of the parotid gland or APG tumours that underwent surgical 
treatment were included. APG tumours comprised 1.23% of overall parotid tumours 
(6/488) and had a malignancy rate of 33.3% (2/6). There were three males and three 
females with mean age of 39 (range, 14-70). A total of 5 of 6 parotidectomies entailed 
superficial lobectomy, while one was total parotidectomy with composite resection of 
masseter muscle. Concomitant selective lymphadenectomy was carried out in 3 of 6 
patients. At 5 years disease-free survival was 83.3%. Mean follow-up was 161 months 
(range, 14-253). Although nonsalivary diagnoses frequently occur in the buccal area, APG 
tumours should be considered in every differential diagnosis in patients presenting with a 
mid-cheek mass. From oncosurgical, cosmetic and functional standpoint, treatment by 
facelift parotidectomy or ''S-incision'' with concomitant superficial lobectomy is 
recommended surgical approach, while high-grade malignancies require total 
parotidectomy with regional lymphadenectomy. 
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INTRODUCTION 
 
The evaluation of a mid-cheek mass represents a significant diagnostic and therapeutic 
challenge. Benign and malignant lesions in this area may arise from soft tissues of the face, 
including the skin, lymphatics, skin adnexa, neural, and salivary structures1. 
The accessory parotid gland (APG) has been described as salivary tissue that is anterior and 
anatomically separate from the main body of the parotid gland and adjacent to Stensen's 
duct by way of one or multiple secondary connections. Frommer2, in his study of cadaveric 
dissections, found an APG in 21% of individuals, although some authors reported 
incidences as high as 56%3. Although the APG is a common anatomical variation, APG 
tumours are extremely rare, with a reported incidence of 1 to 7.7% of all parotid gland 
tumours, and a malignancy rate from 26 to 50%4,5. So far, 157 lesions arising from 
accessory parotid gland have been reported in the English-language literature, including 54 
malignant tumours, 80 benign tumours, and 23 nontumour lesions6,7. There are few larger 
series describing APG tumours4-9. To our knowledge, this is second largest European series 
regarding APG tumours. We report on 6 patients having APG tumours with emphasis on 
diagnosis and clinical features, as well as the indications and rationale for different 
treatment approaches. 
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MATERIALS AND METHODS 
 
Patients were identified through a database search of salivary gland tumours at the 
Department of Maxillofacial Surgery, University of Zagreb School of Medicine, University 
Hospital Dubrava, for the period between January 1, 1985 and December 31, 2008. Patients 
with primary tumours of the parotid gland or APG tumours that underwent surgical 
treatment were included. Among these tumours, patients with primary parotid gland 
tumours and patients with anterior process or extension of the main parotid gland were 
analyzed separate from patients with primary APG tumours. Patients with normal salivary 
tissue in accessory parotid lobes and patients with heterotopic (ectopic) salivary gland 
tissues were excluded. The medical records of patients who were surgically treated for APG 
tumours were reviewed. Radiotherapy was indicated in cases of malignant disease of the 
APG. Follow-up intervals were calculated in months from the date of first treatment at our 
Department to the date of last follow-up or death. The follow-up interval was concluded on 
December 31, 2011. 
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RESULTS 
 
During the 24-year period, 488 patients with primary parotid tumours underwent surgical 
treatment. APG tumours comprised 1.23% of overall parotid tumours (6/488) and had a 
malignancy rate of 33.3% (2/6). The clinical features, diagnosis, treatments and outcomes 
are summarized in Table 1. 
There were three males and three females with a mean age of 39 years (range, 14-70). All 
patients except one had undergone no previous treatment. This latter patient is a 48-years-
old woman who received surgical treatment for a pleomorphic adenoma elsewhere (mid-
cheek incision directly over the tumour) and has been referred to our Department because 
of local recurrence (Figure 1). 
Three patients presented with a painless, progressively enlarging buccal mass, while two 
patients had painful lesions at the same location. One patient had painless mid-cheek lesion 
with numbness of the cheek and upper lip. 
All patients had undergone FNAB preoperatively and the results were identical to those 
provided by patohistological analysis following operation. Histologically, of the 6 APG 
tumours, there were three pleomorphic adenomas (one of which was multilocular), one 
myoepithelioma, one adenoid cystic carcinoma and one high-grade mucoepidermoid 
carcinoma. Two patients with malignant disease underwent adjuvant postoperative 
irradiation what included 27 fractions of 2 Gy given over 4 weeks. A total of 5 out of 6 
parotidectomies entailed a superficial lobectomy, while one was a total parotidectomy with 
composite resection of the masseter muscle in case of high-grade mucoepidermoid 
carcinoma. In four cases of superficial parotidectomy buccal branches were in intimate 
 7
relationship with the APG tumour and were sacrificed in order to achieve macroscopic 
tumour clearance. Apart from these patients in whom the facial nerve was partially 
sacrificed, two patients developed a facial palsy which fully recovered. Concomitant neck 
dissection was carried out in 3 of the 6 patients (50%), and comprised two selective neck 
dissections of level 2 and one selective neck dissection of levels 1 and 2. 
Lymphadenectomies were electively performed in suspicious cases, though they yielded 
negative neck nodes. No postoperative complications were detected. 
At the time of follow-up, five patients were disease-free, while one patient developed a 
locoregional recurrence with distant metastases of a high-grade mucoepidermoid carcinoma 
8 months after initial surgical intervention and died 6 months later. At 5 years disease-free 
survival was 83.3%. Mean follow-up was 161 months (range, 14-253).
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DISCUSSION 
 
The differential diagnosis of a mid-cheek masses includes parotid gland epidermoid cyst or 
arterivenous malformation, Stensen's duct stone, lipoma, neoplasm, hemangioma or 
adnexal tumours, neural tumours, hematoma, benign and malignant adenopathy, metastatic 
disease, and benign and malignant tumours of the accessory parotid tissue1,10. The 
accessory parotid gland is an isolated cluster of salivary tissue which lies between the 
buccal and zygomatic branches of the facial nerve on the masseter muscle and occurs 
typically around the midpoint of an imaginary line drawn from the tragus of the ear to a 
point halfway between the ala of the nose and the vermillion border of the upper lip11. 
Johnson and Spiro4 retrospectively reviewed 2 261 parotid gland tumours during a 40 year 
period, and found that 1% arose in APGs. Of these APG tumours, more than half proved 
malignant. Perzik et al.5  reported a 7.7%  incidence of APG tumours among all parotid 
gland tumours with a malignancy rate of 26%. The only study of a metastatic spread to the 
APG has been reported by Goldberg et al.12. Combined with previously reported 157 cases, 
there are 84 benign tumours, 56 malignant tumours, and 23 nontumours lesions in the total 
163 cases (Table 2). 
According to the literature, APG tumours most often present as an asimptomatic 
progressively enlarging cheek mass and usually occur in patients with a mean age ranging 
from 45 to 64.4 years at the time of presentation1,6,7,9. In contrast, in this study group, 
patients were younger, with a mean age of 39 and 50% of patients presented with 
simptomatic lesions which included different head and neck complaints such as pain and 
numbness in mid-cheek area. Similar results were reported by Sun et al.13. Patients were 
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evaluated through careful physical examination and additional diagnostic tools including 
fine-needle aspiration (FNA), computed tomography (CT) and magnetic resonance (MR). 
Neck dissection was performed in cases of malignant or recurrent APG tumours. In this 
study, the incidence of APG tumours was 1.23% with a malignacy rate of 33.3% which is 
in range with prior reports4,5. One patient with a malignant lesion of the APG died due to 
locoregional recurrence and distant disease from high grade mucoepidermoid carcinoma. 
Similar biological behavior of mucoepidermoid carcinoma arising from APG tissue has 
been described before14. 
After differential diagnosis, the second important question concerns the extent of surgical 
treatment. There are four surgical approaches in management of APG tumours: the standard 
''S-incision'' or facelift parotidectomy approach, intraoral approach and cheek incision 
directly over the tumour. The latter one is associated with an increased incidence of facial 
nerve injury because of the superficial location of the buccal and zygomatic branches of the 
seventh cranial nerve. Johnson and Spiro4 reported a 40% incidence of facial nerve injury 
for tumours approached via a direct skin incision over the mass. Furthermore, a limited 
incision is associated with a high incidence of local recurrence brought on by inadequate 
excision margins and an unsightly scar. The intraoral approach also places the facial nerve 
at high risk because of difficulty in optimal exposure15. In the context of the nerve-tumour 
relationship, a standard facelift parotidectomy approach is advisable. Once a standard 
incision is made, a concomitant superficial parotidectomy is recommended. This allows 
identification of the main facial nerve trunk with tracing of all its branches. Furthermore, 
this surgical technique provides excellent exposure which minimizes the risk of 
complications during excision of these tumours (Figure 2). Johnson and Spiro4 reported no 
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postoperative facial nerve palsies in 13 patients undergoing a standard parotidectomy 
approach. Perzik et al.5 reported no facial nerve injuries in 20 modified preauricular 
approaches. In addition, this approach hides unsightly scars within natural skin creases and 
hairlines, giving the best cosmetic result (Figure 3). Most importantly, this treatment 
modality provides adequate resection which minimizes the risk of local recurrence. In our 
experience, the standard parotidectomy approach (facelift incision) with superficial 
parotidectomy in conjunction with excision of the APG tumour is the recommended 
surgical approach (Figure 4). According to the recent publications, Xie et al.16 introduced a 
minimally invasive endoscopic approach via a small preauricular incision performed on 5 
patients with benign APG tumours and no postoperative complications and recurrences 
were found. Primarily due to oncological reasons, we doubt that the minimally invasive 
endoscopic resection is the best method of treatment for tumours of the APG. This opinion 
is supported by previous studies which reported  reduced recurrence rates (less than 4%) 
associated with extended surgical techniques compared with the high incidence of 
recurrence (25-40%) resulting from enucleation among patients with pleomorphic adenoma 
of the parotid gland17-19. In addition, surgery of recurrent parotid gland tumours carries 
considerable risk of facial nerve injury which varies from 15 to 30% and the chance of 
recurrence is high ranging from 15 to 75%20-25. Moreover, one year of follow-up is not a 
sufficient time interval for recurrence detection since recurrent benign parotid gland 
tumours occur 3 to 9 years after initial surgical treatment21,25-27. 
A clear weakness of this retrospective study is the small sample size. However, given the 
rarity of this entity, it’s difficult to find larger series. Indications for elective neck dissection 
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in patients with malignant parotid and APGT tumours remains unclear. Further 
investigations are necessary in order to improve our better understanding of the subject.   
In conclusion, APG tumours are extremely rare and represent a considerable diagnostic 
problem. Although nonsalivary diagnoses frequently occur in the buccal area, APG 
tumours should be considered in every differential diagnosis in patients presenting with a 
mid-cheek mass. In this study group, patients with APG tumours were younger than most 
reports in the literature state and half of them presented with a symptomatic mid-cheek 
mass unlike the typical asymptomatic cases from the literature. In order to establish the 
correct diagnosis, we advocate proper preoperative evaluation which includes a detailed 
physical examination, FNA and imaging techniques (CT and MR scans). Surgical resection 
remains the mainstay of treatment for both parotid and APG tumours. From oncosurgical, 
cosmetic, and functional standpoints, treatment by facelift parotidectomy approach or ''S-
incision'' with concomitant superficial lobectomy is the recommended surgical approach, 
while a high-grade histological appearance requires total parotidectomy. 
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CAPTIONS TO ILLUSTRATIONS 
FIGURE (1) Preoperative photograph showing scar (arrow) from mid-cheek incision. 
 
 
FIGURE (2) Intraoperative photograph. 
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FIGURE (3) Postoperative photograph (27 months after surgery). 
 
 
FIGURE (4) Intraoperative specimen showing superficial lobe of the parotid gland (dashed 
arrow), Stensen’s duct (dotted arrow) and masseter muscle with APG tumour (solid arrow). 
 
